DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
scientists and collaborators related to Inspire will present
information from five abstracts at the 2007 Association for
Research in Vision and Ophthalmology (ARVO) Annual Meeting to be
held May 6-10, 2007 in Ft. Lauderdale, Florida. These abstracts,
which will be presented in poster sessions, are related to three of
Inspire's programs, including bacterial conjunctivitis, dry eye and
allergy.
Two poster presentations are related to AzaSite(TM)
(azithromycin ophthalmic solution) 1%, a treatment for bacterial
conjunctivitis, which was recently approved by the U.S. Food and
Drug Administration.
-- Development of a Commercial Eye Drop Formulation of
Azithromycin
L.M. Bowman, E. Si, J. Pang, M. Friedlaender
Sunday, May 6, 2007, 2:30 p.m. - 4:15 p.m.
-- Frequent Dosing With Topical 1% Azithromycin is Effective in
Reducing Azithromycin-Resistant Pseudomonas aeruginosa Colony
Counts in a NZW Rabbit Model
K.A. Yates, E.G. Romanowski, R.P. Kowalski, F.S. Mah, Y.J.
Gordon
Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.
Three poster presentations are related to Inspire's development
programs in dry eye disease and allergies.
-- Effect of Diquafosol on Ocular Surface Health in Dry Eye
Disease
R. Brazzell, D.J. Kellerman, A. Schaberg, B.Yerxa, T. Durham
Sunday, May 6, 2007, 11:00 a.m. - 12:45 p.m.
-- A Correlation Between Central Corneal Staining and Visual
Function in Patients Diagnosed With Dry Eye
G.W. Ousler, III, K. Brazzell, T. Durham, P. Walker, R.T.
Anderson, M.B. Abelson
Sunday, May 6, 2007, 11:00 a.m. - 12:45 p.m.
-- The Pharmacological Properties of Epinastine on Histamine H2
and H4 Receptors
S.C. Wolff, K. Brubaker, R.C. Wright, J.L. Boyer
Monday, May 7, 2007, 3:00 p.m. - 4:45 p.m.
These po
'"/>
Page: 1 2 3 Related medicine technology :1.
Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference2.
Inspire Announces Presentations at Two European Scientific
Conferences3.
Inspire Announces Positive Results of Phase 2 Trial of Epinastine
Nasal Spray for Seasonal Allergic Rhinitis4.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial5.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis6.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis7.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial8.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine9.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis10.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone11.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease